HNRNPUL2-BSCL2 (Gene)

Organism:

Homo sapiens

Taxonomy (Entity type)

Gene:

HNRNPUL2-BSCL2 associations

Collection (Entity type)

Id:ENSG00000234857

Entrez:100534595

Ensembl:ENSG00000234857

Description:HNRNPUL2-BSCL2 readthrough (NMD candidate)

This locus represents naturally occurring read-through transcription between the neighboring HNRNPUL2 (heterogeneous nuclear ribonucleoprotein U-like 2) and BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 (seipin)) genes on chromosome 11. The read-through transcript is a candidate for nonsense-mediated mRNA decay (NMD), and is unlikely to produce a protein product. [provided by RefSeq, Mar 2011]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View HNRNPUL2-BSCL2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with HNRNPUL2-BSCL2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using HNRNPUL2-BSCL2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for HNRNPUL2-BSCL2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with HNRNPUL2-BSCL2.

Results found

Linked to

	Label	Description
	GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 11 v 12 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE165960 MEK inhibition 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE197571 FOXM1 RNF112 overexpression MGC-803 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128885 deferiprone macrophage 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE203329 HCC knockout 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 8 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE108464 AZ-628 11 v 12 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE165960 MEK inhibition 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE197571 FOXM1 RNF112 overexpression MGC-803 2 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE128885 deferiprone macrophage 0 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE203329 HCC knockout 2 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 8 v 9 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.